{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:16Z","timestamp":1784408836207,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,14]]},"DOI":"10.7759\/cureus.85981","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T08:00:16Z","timestamp":1749888016000},"source":"Crossref","is-referenced-by-count":1,"title":["Porto-Sinusoidal Vascular Liver Disease Associated With Trastuzumab Emtansine: A Case Report"],"prefix":"10.7759","author":[{"given":"Ana Rita","family":"Antunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Carmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Pereira","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina Antunes","family":"Salvado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel O","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.033","article-title":"Porto-sinusoidal vascular disorder","volume":"77","author":"De Gottardi A","year":"2022","unstructured":"De Gottardi A, Sempoux C, Berzigotti A. Porto-sinusoidal vascular disorder. J Hepatol. 2022, 77:1124-35. 10.1016\/j.jhep.2022.05.033","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.035","article-title":"Porto-sinusoidal vascular liver disorder with portal hypertension: natural history and long-term outcome","volume":"82","author":"Magaz M","year":"2025","unstructured":"Magaz M, Giudicelli-Lett H, Abraldes JG, et al.. Porto-sinusoidal vascular liver disorder with portal hypertension: natural history and long-term outcome. J Hepatol. 2025, 82:72-83. 10.1016\/j.jhep.2024.07.035","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24422","article-title":"Idiopathic noncirrhotic portal hypertension","volume":"54","author":"Schouten JN","year":"2011","unstructured":"Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011, 54:1071-81. 10.1002\/hep.24422","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100814","article-title":"Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis","volume":"5","author":"Hui VW","year":"2023","unstructured":"Hui VW, Wong GL, Wong VW, et al.. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis. JHEP Rep. 2023, 5:100814. 10.1016\/j.jhepr.2023.100814","journal-title":"JHEP Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips GD","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, et al.. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-90. 10.1158\/0008-5472.CAN-08-1776","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220536","article-title":"Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT","volume":"305","author":"Choi SJ","year":"2022","unstructured":"Choi SJ, Lee SS, Jung KH, et al.. Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT. Radiology. 2022, 305:606-13. 10.1148\/radiol.220536","journal-title":"Radiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014545354","article-title":"Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate","volume":"48","author":"Corrigan PA","year":"2014","unstructured":"Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. Ann Pharmacother. 2014, 48:1484-93. 10.1177\/1060028014545354","journal-title":"Ann Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-019-00392-4","article-title":"Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer","volume":"9","author":"Fujii Y","year":"2020","unstructured":"Fujii Y, Doi M, Tsukiyama N, et al.. Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer. Int Cancer Conf J. 2020, 9:18-23. 10.1007\/s13691-019-00392-4","journal-title":"Int Cancer Conf J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8543","article-title":"Nodular regenerative hyperplasia after treatment with trastuzumab emtansine","volume":"34","author":"Force J","year":"2016","unstructured":"Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, Vuppalanchi R. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol. 2016, 34:e9-12. 10.1200\/JCO.2013.49.8543","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.7207","article-title":"Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?","volume":"17","author":"Lepelley M","year":"2018","unstructured":"Lepelley M, Allouchery M, Long J, et al.. Nodular regenerative hyperplasia induced by trastuzumab emtansine: role of emtansine?. Ann Hepatol. 2018, 17:1067-71. 10.5604\/01.3001.0012.7207","journal-title":"Ann Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5902","article-title":"A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine","volume":"30","author":"Krop IE","year":"2012","unstructured":"Krop IE, LoRusso P, Miller KD, et al.. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012, 30:3234-41. 10.1200\/JCO.2011.40.5902","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220910252","article-title":"Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: a case report","volume":"26","author":"Hassan C","year":"2020","unstructured":"Hassan C, Correal F, V\u00e9zina G, Yelle L, Adam JP. Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: a case report. J Oncol Pharm Pract. 2020, 26:1780-4. 10.1177\/1078155220910252","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/377496-porto-sinusoidal-vascular-liver-disease-associated-with-trastuzumab-emtansine-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T08:00:17Z","timestamp":1749888017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/377496-porto-sinusoidal-vascular-liver-disease-associated-with-trastuzumab-emtansine-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.85981","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,14]]}}}